Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026)
Zymeworks (ZYME) reported Non-Current Deferred Tax Liability of $3.8 million for Q1 2026, down 20.52% on a YoY basis from $4.8 million in Q1 2025, and down 36.51% sequentially from $6.0 million in Q4 2025.
Zymeworks (ZYME) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 20.52% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 20.52% YoY), and the FY2025 full-year result was $6.0 million, down 35.91% from the prior year.
- Non-Current Deferred Tax Liability slipped to $3.8 million in Q1 2026, from $6.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $13.0 million in Q4 2023 to a low of $1.6 million in Q3 2022.
- A 5-year average of $4.4 million and a median of $3.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 627.63% in 2023 and sank 35.91% in 2025, its largest moves.
- Tracing ZYME's Non-Current Deferred Tax Liability over 5 years: stood at $1.8 million in 2022, then jumped by 627.63% to $13.0 million in 2023, then decreased by 27.7% to $9.4 million in 2024, then slumped by 35.91% to $6.0 million in 2025, then tumbled by 36.51% to $3.8 million in 2026.
- Business Quant data shows ZYME's Non-Current Deferred Tax Liability at $3.8 million in Q1 2026, $6.0 million in Q4 2025, and $4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.83 Mn |
| Mar 31, 2026 | 3.83 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Sep 30, 2025 | 4.77 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Mar 31, 2025 | 4.82 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Dec 31, 2024 | 9.41 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Jun 30, 2024 | 3.40 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Mar 31, 2024 | 3.35 Mn |
| Dec 31, 2023 | 13.01 Mn |
| Dec 31, 2023 | 13.01 Mn |